<unk> , sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion.<unk>  was approved for medical use in the United States in February 2020.
Eptinezumab
Ustekinumab
Olaratumab
Evinacumab
Emapalumab
Risankizumab
Lanadelumab
Avelumab